Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

By E. Sievers, R. Larson, E. Stadtmauer, E. Estey, B. Löwenberg, H. Dombret, C. Karanes, M. Theobald, J. Bennett, M. Sherman and 6 more. Journal of Clinical Oncology, 2001

904 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/95bfd522d28d4c39add8489efef144e7237cc4ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Senter
2. Kevin J. Hamblett
3. D. Chace
4. Michael M C Sun
5. J. Lenox
6. C. Cerveny
7. K. Kissler
8. Starr X Bernhardt

Citations in the corpus

• Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate (2004, background): “Gemtuzumab ozogamicin, an antibody-drug conjugate that is composed of the potent DNA minor groove binder calicheamicin linked covalently to an anti-CD33 mAb (8), was approved in 2000 by the United States Food and Drug Administration for the treatment of patients with relapsed acute myeloid leukemia ”
• Antibody-drug conjugates: recent advances in conjugation and linker chemistries (2016, methodology): “Another example is the anti-CD33 antibody calicheamicin conjugate, Mylotarg (Linenberger et al., 2001; Sievers et al., 2001).”